- •Preface
- •Contributors
- •Dedication
- •INFECTIOUS DISEASES
- •ACINETOBACTER
- •BACILLUS SPECIES INFECTIONS
- •ESCHERICHIA COLI
- •GONOCOCCAL OCULAR DISEASE
- •INFECTIOUS MONONUCLEOSIS
- •MICROSPORIDIAL INFECTION
- •MOLLUSCUM CONTAGIOSUM
- •MORAXELLA
- •PROPIONIBACTERIUM ACNES
- •PROTEUS
- •PSEUDOMONAS AERUGINOSA
- •STREPTOCOCCUS
- •VARICELLA AND HERPES ZOSTER
- •PARASITIC DISEASES
- •PEDICULOSIS AND PHTHIRIASIS
- •NUTRITIONAL DISORDERS
- •INFLAMMATORY BOWEL DISEASE
- •DISORDERS OF CARBOHYDRATE METABOLISM
- •MUCOPOLYSACCHARIDOSIS IH
- •MUCOPOLYSACCHARIDOSIS IH/S
- •MUCOPOLYSACCHARIDOSIS II
- •MUCOPOLYSACCHARIDOSIS III
- •MUCOPOLYSACCHARIDOSIS IV
- •MUCOPOLYSACCHARIDOSIS VI
- •MUCOPOLYSACCHARIDOSIS VII
- •DISORDERS OF LIPID METABOLISM
- •HEMATOLOGIC AND CARDIOVASCULAR DISORDERS
- •CAROTID CAVERNOUS FISTULA
- •DERMATOLOGIC DISORDERS
- •ERYTHEMA MULTIFORME MAJOR
- •CONNECTIVE TISSUE DISORDERS
- •PSEUDOXANTHOMA ELASTICUM
- •RELAPSING POLYCHONDRITIS
- •UVEITIS ASSOCIATED WITH JUVENILE IDIOPATHIC ARTHRITIS
- •WEGENER GRANULOMATOSIS
- •WEILL–MARCHESANI SYNDROME
- •SKELETAL DISORDERS
- •PHAKOMATOSES
- •NEUROFIBROMATOSIS TYPE 1
- •STURGE–WEBER SYNDROME
- •NEUROLOGIC DISORDERS
- •ACQUIRED INFLAMMATORY DEMYELINATING NEUROPATHIES
- •CREUTZFELDT–JAKOB DISEASE
- •NEOPLASMS
- •JUVENILE XANTHOGRANULOMA
- •LEIOMYOMA
- •ORBITAL RHABDOMYOSARCOMA
- •SEBACEOUS GLAND CARCINOMA
- •SQUAMOUS CELL CARCINOMA
- •MANAGEMENT OF SCLERAL RUPTURES 871.4 AND LACERATIONS 871.2
- •IRIS LACERATIONS 364.74, IRIS HOLES 364.74, AND IRIDODIALYSIS 369.76
- •ORBITAL IMPLANT EXTRUSION
- •SHAKEN BABY SYNDROME
- •PAPILLORENAL SYNDROME
- •ANTERIOR CHAMBER
- •CHOROID
- •ANGIOID STREAKS
- •CHOROIDAL DETACHMENT
- •SYMPATHETIC OPHTHALMIA
- •CONJUNCTIVA
- •ALLERGIC CONJUNCTIVITIS
- •BACTERIAL CONJUNCTIVITIS
- •LIGNEOUS CONJUNCTIVITIS
- •OPHTHALMIA NEONATORUM
- •CORNEA
- •BACTERIAL CORNEAL ULCERS
- •CORNEAL MUCOUS PLAQUES
- •CORNEAL NEOVASCULARIZATION
- •FUCHS’ CORNEAL DYSTROPHY
- •KERATOCONJUNCTIVITIS SICCA AND SJÖGREN’S SYNDROME
- •LATTICE CORNEAL DYSTROPHY
- •NEUROPARALYTIC KERATITIS
- •PELLUCID MARGINAL DEGENERATION
- •EXTRAOCULAR MUSCLES
- •ACCOMMODATIVE ESOTROPIA
- •CONVERGENCE INSUFFICIENCY
- •MONOFIXATION SYNDROME
- •NYSTAGMUS
- •EYELIDS
- •BLEPHAROCHALASIS
- •BLEPHAROCONJUNCTIVITIS
- •EPICANTHUS
- •FACIAL MOVEMENT DISORDERS
- •FLOPPY EYELID SYNDROME
- •MARCUS GUNN SYNDROME
- •SEBORRHEIC BLEPHARITIS
- •XANTHELASMA
- •GLOBE
- •BACTERIAL ENDOPHTHALMITIS
- •FUNGAL ENDOPHTHALMITIS
- •INTRAOCULAR PRESSURE
- •ANGLE RECESSION GLAUCOMA
- •GLAUCOMA ASSOCIATED WITH ELEVATED VENOUS PRESSURE
- •GLAUCOMATOCYCLITIC CRISIS
- •NORMAL-TENSION GLAUCOMA (LOW-TENSION GLAUCOMA)
- •IRIS AND CILIARY BODY
- •ACCOMMODATIVE SPASM
- •LACRIMAL SYSTEM
- •LACRIMAL HYPOSECRETION
- •DISLOCATION OF THE LENS
- •LENTICONUS AND LENTIGLOBUS
- •MICROSPHEROPHAKIA
- •MACULA
- •CYSTOID MACULAR EDEMA
- •EPIMACULAR PROLIFERATION
- •OPTIC NERVE
- •ISCHEMIC OPTIC NEUROPATHIES
- •TRAUMATIC OPTIC NEUROPATHY
- •ORBIT
- •EXTERNAL ORBITAL FRACTURES
- •INTERNAL ORBITAL FRACTURES
- •OPTIC FORAMEN FRACTURES
- •RETINA
- •ACQUIRED RETINOSCHISIS
- •ACUTE RETINAL NECROSIS
- •DIFFUSE UNILATERAL SUBACUTE NEURORETINITIS
- •RETINOPATHY OF PREMATURITY
- •SCLERA
- •SCLEROMALACIA PERFORANS
- •VITREOUS
- •VITREOUS WICK SYNDROME
- •Index
Morse PH: Elschnig’s spots and hypertensive choroidopathy. Am J Ophthalmol 66:844–852, 1968.
Perkovich BT, Meyers SM: Systemic factors affecting diabetic macular edema. Am J Ophthalmol 105:211–212, 1988.
Puliafito CA, et al: Imaging macular diseases with ocular coherence tomography. Ophthalmology 102:217–229, 1995.
Tso MOM, Abrams GW, Jampol LM: Hypertensive retinopathy, choroidopathy, neuropathy. In: Singerman LJ, Jampol LM, eds: Retinal and choroidal manifestations of systemic disease. Baltimore, Williams & Wilkins, 1991:79–127.
Tso MOM, Jampol LM: Pathophysiology of hypertensive retinopathy. Ophthalmology 89:1132–1145, 1982.
Walsh JB: Hypertensive retinopathy: description, classification, and prognosis. Ophthalmology 89:1127–1131, 1982.
Wolf S, et al: Quatification of retinal capillary density and flow velocity in patients with essential hypertension. Hypertension 23:464–467, 1994.
Wong TY, et al: Atherosclerosis Risk in Communities Study. Retinal arteriolar diameter and hypertension. Ann Intern Med 140:248–255, 2004.
Wong TY, et al: Retinal microvascular abnormalities and ten-year cardiovascular mortality. A population-based case-control study. Ophthalmology 110:933–940, 2003.
163 PAPILLORENAL SYNDROME
743.57, 753.0
(Renal–Coloboma Syndrome)
Cameron F. Parsa, MD
Baltimore, Maryland
normal in size, and vesicoureteral reflux can be an associated finding. Patients may be asymptomatic until renal failure is advanced. Not infrequently, both patient and physician are unaware that the ocular and renal findings are related.
Infrequently reported until recently, papillorenal syndrome remains underdiagnosed. Disk excavations may be misinterpreted as acquired due to glaucoma, or they may be thought to represent atypical bilateral morning glory anomaly or optic pit. Many are simply labeled colobomatous although they do not possess the features of true colobomas.
The syndrome is passed down in an autosomal dominant fashion with variable expressivity and de novo mutations also occur. It is important to examine family members whenever the condition is diagnosed and to provide family counseling.
Some affected families have a mutation in the homeobox gene PAX2. Often, however, no mutation can be found, implicating other genes to be involved as well.
COURSE/PROGNOSIS
The ocular course is highly variable; many patients have superonasal field defects but otherwise normal vision. Some patients develop nonrhegmatogenous serous retinal detachments, leading to severe visual loss. The propensity for retinal detachment is related to the degree of thinning of the neuroretinal rim which may allow cerebrospinal fluid (CSF) to seep into the subretinal space. Spontaneous reattachments may occur, leaving behind a characteristic pattern of retinal pigment epithelial changes. The small, or dysplastic kidneys, often lead to chronic glomerulonephropathy and proteinuria. Although some patients eventually require dialysis and renal transplantation, others remain entirely asymptomatic.
ETIOLOGY/INCIDENCE
Papillorenal syndrome (sometimes inaccurately called renalcoloboma syndrome) is an inherited condition often characterized by the association of bilateral, centrally excavated (‘vacant’) optic disks with multiple cilioretinal vessels (Figure 163.1) and dysplastic kidneys. Visual acuity is normal unless secondary serous retinal detachments develop. Kidneys may be small or
DIAGNOSIS
Laboratory findings
Diagnosis has been hampered in the past by the lack of clear nomenclature for disk anomalies. Often erroneously referred to as a coloboma, the disks in this syndrome present with characteristics distinct from actual colobomas, related to failure of
a |
b |
FIGURE 163.1. a) Fundus photos show vessels leaving and entering from the disc periphery. Note bending of vessels making hairpin turns over the rim of each disc. Near the center of the left disc (b), there is a very attenuated central vessel. The variable lack of persisting central vascular and glial structures may give the discs a ‘vacant’ appearance, as seen here.
163 CHAPTERSyndrome Papillorenal •
301
Conditions or Diseases Unclassified • 15 SECTION
the embryonic optic fissure to close, and from other optic disk anomalies.
●The most characteristic feature is the cilioretinal blood supply of the retina compensating for an attenuation or absence of central retinal vessels. A multiplicity of peripheral arteries and veins are visible that bend and make hairpin turns over and into the neural rim of the disk, indicating their cilioretinal origin. If present, the variably attenuated central retinal vein and artery remain centrally located in the disk (Figure 163.1b). Doppler ultrasonography often reveals extensive anastomoses between such cen- trally-placed vessels and the ciliary circulation deeper within the nerve.
often are present, they are due to hypoplastic retinal development rather than to acquired nerve fiber defects.
PROPHYLAXIS
No prophylaxis is known other than the identification of affected individuals, examination of family members, and genetic counseling.
TREATMENT
●The disks may possess a broad, central excavation, with a Individuals with these findings generally have normal visual
variable amount of glial tissue centrally. |
acuity. Those with large disc excavations and potential defects |
||
● The findings are bilateral. There may be asymmetry in the |
in Kuhnt intermediary |
tissue which allows subretinal CSF |
|
appearance of central vessels, though both eyes have an |
seepage are at risk for |
developing secondary serous |
retinal |
essentially cilioretinal origin of their blood supply. |
detachments. There have been reports of varying |
degrees |
|
●The disks are normal in size without peripapillary excavaof success in reattaching these retinas using methods such
tions or staphyloma.
●Superonasal field defects may be present.
The combined findings may sometimes create the appearance of centrally ‘vacant’ disks, which should hint to the underlying diagnosis.
●Ultrasonography may show bilateral, variably small or normal-sized, echogenic, dysplastic kidneys. In some cases, Doppler ultrasound may reveal high resistive indices to blood flow.
●Serum chemistry may indicate elevated blood urea nitrogen and creatinine levels, and urinalysis may reveal proteinuria. Microalbuminuria testing is a sensitive marker for disease.
●Blood can be drawn for PAX2 mutation analysis which is positive in some families.
Note: Unlike true or ‘typical’ colobomas, the dysplastic, vacant disks noted in this syndrome do not have central vessels displaced superiorly, nor is the area of the disk excavation greatest inferonasally. Thus, the alternative appellation for this entity, ‘renal-coloboma syndrome,’ is a misnomer and should be avoided since it implies a failure of embryonic fissure closure rather than a genetic anomaly affecting angiogenesis-mediated (as opposed to vasculogenesis) vessel formation.
Differential diagnosis
●Unlike a coloboma, there is no superodisplacement of blood vessels, nor is the disk excavation centered inferonasally in association with retinal or choroidal defects.
●Unlike morning glory anomaly, the findings are essentially bilateral and associated with good central vision (unless a serous retinal detachment occurs secondarily). The disk size is normal, and the central excavation is broad based rather than funnel shaped. Both conditions, however, do share the common feature of multiplicity of cilioretinal vessels.
●Unlike optic pits, the excavations are broad and not located toward the temporal aspect of the disc. Multiple, if not all, vessels enter and leave the disk periphery, bending or making hairpin turns over the neural rim.
●The presence of a central glial tuft and the often extensive, and frequently exclusive, cilioretinal vascular supply should help to exclude glaucoma. Although superonasal field defects
as optic nerve sheath fenestration or vitrectomy with gas bubble injection. Given the underlying etiology, lowering retrolaminar CSF pressure via sheath fenestration, or, alternatively, raising intraocular pressure, may be more effective approaches.
The most important role of the ophthalmologist in these cases is to refer the patient to a nephrologist for an evaluation and ultrasound examination of the kidneys (including Doppler scanning for resistive indices). Many individuals with ocular findings have undiagnosed chronic renal disease. Others may have normal kidney function at the time of their initial examination with abnormal anatomy, and develop premature renal failure years later. The identification of individuals at risk for renal failure may allow the timely institution of renal protective measures such as aggressive blood pressure control. Such measures are recognized to vastly improve renal potential in dysplastic kidneys and defer the need for dialysis and other procedures by many years.
COMPLICATIONS
Complications include serous retinal detachment and renal failure. Pronounced congenital disc excavations may predispose patients with otherwise ‘normal’ intraocular pressures to superimposed acquired glaucoma. Thus, careful evaluation for progressive visual field changes should be performed. Since the retina is congenitally hypoplastic, and the discs dysplastic, field changes are often atypical in form. Baseline stereo disc photos should be obtained for early detection of potential changes in disc morphology.
REFERENCES
Barroso LHL, Hoyt WF, Narahara M: Can the arterial supply of the retina in man be exclusively cilioretinal? J Neurol Ophthalmol 14:87–90, 1994.
Bron AJ, Burgess SEP, Awdry PN, et al: Papillo-renal syndrome: an inherited association of optic disc dysplasia and renal disease: report and review of the literature. Ophthalmic Paediatr Genet 10:185–198, 1989.
Chang S, Haik BG, Ellsworth RM, et al: Treatment of total retinal detachment in morning glory syndrome. Am J Ophthalmol 97:596–600, 1984.
Chen CS, Odel JG, Miller JS, Hood DC: Multifocal visual evoked potentials and multifocal electroretinograms in papillorenal syndrome. Arch Ophthalmol 120:870–871, 2002.
302
Dureau P, Attie-Bitach T, Salomon R, et al: Renal coloboma syndrome. Ophthalmology 108:1912–1916, 2001.
Ford B, Rupps R, Lirenman D, Van Allen MI, et al: Renal-coloboma syndrome: prenatal detection and clinical spectrum in a large family. Am J Med Genet 99:137–141, 2001.
Irvine AR, Crawford JB, Sullivan JH: The pathogenesis of retinal detachment with morning glory disc and optic pit. Retina 6:146–150, 1986.
Parsa CF, Cheeseman EW, Maumenee IH: Demonstration of exclusive cilioretinal vascular system supplying the retina in man: vacant discs. Trans Am Ophthalmol Soc 96:95–109, 1998.
Parsa CF, Silva ED, Sundin OH, et al: Redefining papillorenal syndrome: an underdiagnosed cause of ocular and visual morbidity. Ophthalmology 108:738–749, 2001.
Sanyanusin P, Schimmenti LA, McNoe LA, et al: Mutation of the PAX2 gene in a family with optic nerve colobomas, renal anomalies and vesicoureteral reflux. Nat Genet 9:358–363, 1995.
164VOGT–KOYANAGI–HARADA DISEASE 364.24
(Harada’s Disease; Uveomeningitis)
Russell W. Read, MD
Birmingham, Alabama
in United States studies to over 9% of uveitis cases in Japanese studies. VKH disease affects females more commonly than males. Average age of disease onset is the third to fifth decade of life, but patients as young as 4 years of age have been reported.
COURSE/PROGNOSIS
VKH disease is typically divided into four stages: prodromal, acute uveitic, convalescent, and chronic-recurrent stages. The prodromal stage manifests with predominately neurologic and auditory symptoms including headache, meningismus, tinnitus, and dysacousia. Patients may be diagnosed with aseptic meningitis if they seek medical care prior to the onset of ocular inflammation. The uveitic stage begins a variable time later, but typically within a week, with the onset of a diffuse choroiditis as the hallmark of disease. This may manifest as diffuse choroidal thickening (best demonstrated on ultrasonography), exudative retinal detachments, and papillitis. Vitreous and anterior chamber cell may be present. Fluorescein angiography reveals multiple pinpoint areas of subretinal leakage with eventual pooling in the subretinal space (Figure 164.1 and 164.2). Ciliary body edema and detachment may occur, with forward rotation of the lens-iris diaphragm and a resultant shallowed angle. As the inflammatory attack subsides, typically following
ETIOLOGY/INCIDENCE
Vogt–Koyanagi–Harada (VKH) disease is characterized by inflammation involving the eye, inner ear, skin, hair, and meninges of the central nervous system, but the exact cause remains unknown. Immunohistochemistry of ocular and skin specimens have shown an infiltration of CD4+ T-cells, epithelioid cells, and multinucleated giant cells, indicative of granulomatous inflammation. Evidence increasingly suggests that this attack is directed against an as of yet unidentified component of the melanocytes contained in the targeted tissues. This data includes studies revealing that immunization of rats or Akita dogs with tyrosinase family peptides produces a uveitis that is similar to human VKH disease. Human studies have shown that cerebrospinal fluid obtained from patients with VKH disease contains melanin-laden macrophages. This finding could be due to directed phagocytosis of melanin or to non-specific phagocytosis of melanin liberated during inflammation. However, peripheral blood lymphocytes from patients with VKH disease proliferate upon stimulation with tyrosinasefamily peptides, suggesting that melanin-related components are an immunological target. The exact inciting event that leads to the autoimmune attack against melanin is unknown, but several possibilities exist. Occult trauma of melanocytecontaining tissues could lead to a sensitization to melanin. Viral infection could likewise cause a collateral sensitization to melanin components. While not conclusive proof, Epstein–Barr virus DNA has been isolated from the vitreous of patients with VKH disease. A genetic predisposition may contribute to disease, with numerous studies showing a strong association with the human leukocyte antigen (HLA) DR4 allele and specifically with HLA-DRB1*0405 and HLA-BRB1*0410 subtypes.
VKH disease is more common in Asians, Asian Indians, Middle Easterners, Hispanics, and American Indians. The condition is rare in Africans and Caucasians. Frequency of disease varies by study clinic, ranging from 1% to 7% of uveitis cases
FIGURE 164.1. Vogt–Kayanagi–Harada syndrome (fluoroscein angiogram).
FIGURE 164.2. Vogt–Kayanagi–Harada syndrome.
Disease164 HaradaCHAPTER–Koyanagi–Vogt •
303
Conditions or Diseases Unclassified • 15 SECTION
treatment, the convalescent stage begins. It is during this stage that variable depigmentation of the eye, skin and hair may occur. Sugiura’s sign, consisting of perilimbal pigment loss, most pronounced at the superior limbus, may develop. Loss of choroidal pigment produces the classic sunset-glow fundus. Areas of hyperpigmentation and pigment clumping in the fundus may develop. Multiple, well-defined yellow nummular chorioretinal scars may develop, primarily in the inferior peripheral fundus. Patients may experience chronic-recurrent disease at any point following resolution of the acute uveitic phase. This recurrent disease is interesting in that it is primarily an anterior uveitis, with a recurrence of posterior segment findings being very uncommon. The recurrent anterior uveitis may be very difficult to control. Anecdotal evidence suggests that early, aggressive treatment of the acute disease may reduce the incidence of both depigmentation and recurrent uveitis.
Ocular complications may develop in VKH disease as they do in other forms of uveitis and the development of complications appears to be a predictor for visual outcome, with those patients that develop fewer complications generally doing better than those who develop more. Cataract, glaucoma, choroidal neovascular membranes, or subretinal fibrosis may occur. Approximately half of patients will maintain vision of at least 20/40.
DIAGNOSIS
Diagnostic criteria exist for VKH disease and require documentation of an absence of prior ocular penetration; absence of evidence of another uveitic condition; presence of bilateral ocular inflammatory disease manifesting as a diffuse choroiditis acutely and ocular pigmentary disturbances late; presence of prodromal neurological or auditory findings; and depigmentation of the skin or hair or loss of hair. Varying combinations of these manifestations result in a diagnosis of probable, incomplete, or complete disease. The reader is referred to the original diagnostic criteria publication for complete details and an explanation of the application of the criteria.
Clinical signs and symptoms
Prodromal and acute uveitic stages
●Ocular findings:
●Anterior segment: anterior chamber cells and flare with keratic precipitates (variably present); anterior chamber shallowing;
●Choroid: diffuse choroiditis, which may be demonstrated as thickening on ultrasonography or multiple areas of dye leakage with subretinal pooling on fluorescein angiogram;
●Retina: exudative retinal detachment; retinal folds or striae;
●Optic nerve: swollen optic disc with hyperemia;
●Vitreous: cells (variably present).
●Extraocular lesions:
●Inner ear: sensorineural hearing loss, especially at high frequencies; tinnitus;
●Neurologic manifestations: headache, meningismus.
Convalescent stage
●Ocular lesions:
●Anterior segment: atrophy of iris stroma; perilimbal vitiligo;
●Choroid: sunset-glow fundus; nummular chorioretinal scars; hyperpigmentation and pigment clumping;
●Retina: choroidal neovascular membrane; subretinal fibrosis.
●Extraocular lesions:
●Inner ear: persistent sensorineural hearing loss, especially at high frequencies;
●Skin, hair: alopecia; vitiligo; poliosis.
Chronic-recurrent stage
●Ocular lesions:
●Anterior segment: anterior chamber cells and flare; keratic precipitates; atrophy of iris stroma; iris nodules; perilimbal vitiligo;
●Choroid: same as Convalescent stage above;
●Retina: same as Convalescent stage above.
●Extraocular lesions:
●Same as Convalescent stage above.
Laboratory findings (in prodromal or acute uveitic stages)
●Lymphocytic pleocytosis of cerebrospinal fluid.
●Diffuse choroidal thickening without evidence of posterior scleritis on ultrasonography.
●Multiple pinpoint areas of leakage with eventual pooling of dye in subretinal space on fluorescein angiography.
●High-frequency hearing deficit on audiometry.
Differential diagnosis
●Sympathetic ophthalmia.
●Posterior scleritis.
●Uveal effusion syndrome.
●Acute posterior multifocal placoid pigment epitheliopathy (APMPPE).
●Sarcoidosis.
●Primary central nervous system lymphoma with ocular involvement.
TREATMENT
Systemic
Common practice among uveitis specialists entails the use of high-dose corticosteroids as initial therapy. Oral or intravenous forms may be used, with recent data suggesting no difference in final visual acuity. Prednisone may be used at 1 mg/kg/day orally or methylprednisolone 500 mg to 1 g per day intravenously, either divided or in a single dose. Methylprednisolone is typically continued for 3 days with tapering accomplished with subsequent oral prednisone.
Similar to other uveitic conditions, if systemic corticosteroids at safe and tolerable doses are insufficient to bring the disease under control or the condition recurs with tapering to a dose less than 10 mg/day prednisone, then non-corticosteroid immunosuppressive agents should be considered. Selection of a specific agent should be based on individualized patient characteristics and comorbidities, as no agents have been shown to be of greater efficacy than any other in treating VKH disease. Use of immunosuppressive agents should be coordinated by an experienced specialist. Agents used to treat VKH disease include antimetabolites, T-cell specific agents, and alkylating agents. Newer biologic agents may be of benefit, but data is lacking at present regarding their use in VKH disease.
304
Ocular
Topical corticosteroids are adequate only as an adjunct in acute disease with posterior segment manifestations, but may be sufficient for a mild recurrent anterior uveitis. Prednisolone acetate 1% is commonly used with the same principles of corticosteroid use for other uveitic entities applying here as well, including frequent enough use to ensure control of disease. With active anterior segment inflammation, cycloplegia should be utilized to prevent posterior synechiae. An agent strong enough to keep the pupil moving should be employed, such as homatropine, scopolamine, or atropine.
Periocular corticosteroid injections via the sub-Tenon’s or orbital floor routes may be used either as primary or adjunctive therapy in acute or recurrent disease, though typically its use as primary therapy occurs in mild cases or where systemic corticosteroid use is contraindicated. This route of administration is especially appealing for asymmetrical disease. Triamcinolone acetonide, triamcinolone diacetate or dexamethasone may be utilized.
Surgical
There is little, if any, role for surgery as a primary therapy for VKH disease. Some clinicians have attempted to drain subretinal fluid that was slow to resolve with medication alone, but this should be considered an exceptional situation. Surgery is primarily utilized to address the ocular complications that may occur and includes cataract extraction, glaucoma filtering or shunt surgery, and removal of choroidal neovascular membranes.
COMPLICATIONS
Ocular complications
Cataracts; posterior synechiae; glaucoma (angle-closure or open-angle); choroidal neovascular membranes; subretinal fibrosis; pigment disturbances; optic atrophy.
Extraocular complications
Vitiligo; poliosis; alopecia.
COMMENTS
Ocular complications have been shown to be associated with a longer duration of disease, and an increasing number of cumulative complications is associated with a worse final visual acuity. Anecdotal evidence suggests that early, aggressive therapy, typically with high-dose corticosteroids, reduces the occurrence of complications and recurrent disease. Non-corti- costeroid immunosuppressive agents may be required to achieve and maintain adequate control.
SUPPORT GROUPS
While no VKH specific support groups exist in the United States, groups dedicated to uveitis in general do exist, as follows:
•American Uveitis Society, www.uveitissociety.org
•Immunology and Uveitis Service of the Massachusetts Eye and Ear Infirmary www.uveitis.org
REFERENCES
Hayakawa K, Ishikawa M, Yamaki K: Ultrastructural changes in rat eyes with experimental Vogt-Koyanagi-Harada disease. Jpn J Ophthalmol 48:222–227, 2004.
Moothy RS, Inomata H, Rao NA: Vogt-Koyanagi-Harada syndrome. Surv Ophthalmol 39:265–292, 1995.
Ohno S: Immunological aspects of Behçet’s and Vogt-Koyanagi-Harada’s disease. Trans Ophthalmol Soc UK 101:335–341, 1981.
Read RW: Vogt-Koyanagi-Harada disease. Ophthalmol Clin North Am 15:333–341, 2002.
Read RW, Rechodouni A, Butani N, et al: Complications and prognostic factors in Vogt-Koyanagi-Harada disease. Am J Ophthalmol 131:599– 606, 2001.
Read RW, Holland GN, Rao NA, et al: Revised diagnostic criteria for Vogt- Koyanagi-Harada disease: report of an international committee on nomenclature. Am J Ophthalmol 131:647–652, 2001.
Rubsamen PE, Gass JD: Vogt-Koyanagi-Harada syndrome: clinical course, therapy, and long-term visual outcome. Arch Ophthalmol 109:682– 687, 1991.
Yamaki K, Takiyama N, Itho N, et al: Experimentally induced Vogt- Koyanagi-Harada disease in two Akita dogs. Exp Eye Res 80:273–280, 2005.
Disease164 HaradaCHAPTER–Koyanagi–Vogt •
305
